RECRUITINGINTERVENTIONAL
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
About This Trial
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age 18 and 65 years.
- Both sexes.
- Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Who Should NOT Join This Trial:
- Patients with medication over use headache.
- Bleeding disorders.
- Abnormal neurological examination.
- History of allergy to local anesthetics or BOTOX.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age 18 and 65 years.
* Both sexes.
* Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Exclusion Criteria:
* Patients with medication over use headache.
* Bleeding disorders.
* Abnormal neurological examination.
* History of allergy to local anesthetics or BOTOX.
Treatments Being Tested
DRUG
Sphenopalatine block
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
DRUG
Botulinum Toxin Type A
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Locations (1)
Cairo University
Cairo, Egypt